Zura Bio LTD Form 4 insider transactions

Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.

NASDAQ
Zura Bio Ltd reports the grant of employee stock options to Chief Technology Officer Gary Whale, with vesting conditions tied to continuous service.
NASDAQ
Zura Bio Ltd reports on an executive's stock option grant, detailing vesting schedules and beneficial ownership.
NASDAQ
Zura Bio Ltd reports that Chief Financial Officer Eric J. Hyllengren was granted employee stock options on April 1, 2026.
NASDAQ
Zura Bio Ltd. reports the grant of employee stock options to Chief Legal Officer Kim Davis, with vesting over several years.
NASDAQ
Sandeep Kulkarni, CEO of Zura Bio Ltd., has acquired stock options for 894,000 shares, with vesting scheduled to begin in April 2027.
NASDAQ
Zura Bio Ltd. Director Ajay Nirula was granted 37,812 stock options with an exercise price of $6.53, vesting over one year starting February 21, 2026.
NASDAQ
AI Biotechnology LLC, a 10% owner of Zura Bio Ltd, acquired 2 million Class A Ordinary Shares for $12.5 million in a registered offering.
NASDAQ
Zura Bio Ltd. Director Mark Eisner was granted 37,812 share options with an exercise price of $6.53, vesting over one year.
NASDAQ
Zura Bio Ltd. Director Parvinder Thiara was granted 38,823 share options with an exercise price of $6.36, vesting over one year.
NASDAQ
Zura Bio Ltd's CEO, Sandeep Chidambar Kulkarni, was granted 2,934,107 employee stock options with an exercise price of $6.32, vesting over time.
NASDAQ
Zura Bio Ltd's Chief Financial Officer, Eric J. Hyllengren, was granted 672,000 employee share options with a vesting schedule tied to continuous service.
NASDAQ
Zura Bio Ltd. Director Daniel J. Becker was granted 51,000 share options with an exercise price of $1.02, vesting over one year.
NASDAQ
Director Arnout Ploos van Amstel reports the acquisition of stock options in Zura Bio Ltd.
NASDAQ
Director Someit Sidhu reports acquisition of 51,000 share options in Zura Bio Ltd.
NASDAQ
Director Amit Munshi reports acquisition of share options in Zura Bio Ltd.
NASDAQ
Director Sandeep Chidambar Kulkarni of Zura Bio Ltd. reports acquisition of share options.
NASDAQ
Director Steven J. Schoch of Zura Bio Ltd. reports acquisition of share options.
NASDAQ
Director Neil Murray Hamilton Graham of Zura Bio Ltd. reports acquisition of share options.
NASDAQ
Director Jennifer Jarrett acquired 51,000 share options in Zura Bio Ltd on May 21, 2025, according to a Form 4 filing.
NASDAQ
Verender S. Badial, CFO of Zura Bio Ltd, reports the acquisition of employee share options.
NASDAQ
Gary Whale, Chief Technology Officer of Zura Bio Ltd., reports the acquisition of employee share options.
NASDAQ
Kiran Nistala, Chief Medical Officer of Zura Bio Ltd, reports the acquisition of stock options.
NASDAQ
Zura Bio Ltd's CEO, Robert Lisicki, reports the acquisition of stock options for 1,153,000 Class A Ordinary Shares.
NASDAQ
Kim Davis, Chief Legal Officer of Zura Bio Ltd, reports the acquisition of stock options for 488,800 Class A Ordinary Shares.
NASDAQ
Kim Davis, Chief Legal Officer of Zura Bio Ltd, reports the acquisition of Class A Ordinary Shares through restricted stock units and holdings by a family member.
NASDAQ
Zura Bio Ltd has granted an executive 117,000 share options that vest over one year.
NASDAQ
Zura Bio Ltd. has granted 117,000 share options to Graham Neil Murray Hamilton, vesting over one year.
NASDAQ
Zura Bio Ltd has granted 117,000 share options to Arnout Ploos van Amstel, vesting over one year.
NASDAQ
Zura Bio Ltd. has granted 117,000 share options to Steven J. Schoch, vesting over a one-year period.
NASDAQ
Zura Bio Ltd has granted Sandeep Chidambar Kulkarni 117,000 share options, vesting over one year.